Business Context and Reporting Period
This Form 8-K filing by Omeros Corporation covers the period ending October 21, 2011. The report addresses Item 8.01 (Other Events) concerning a legal proceeding involving a former executive.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure mentioned is approximately $1.3 million in National Institutes of Health grants that are the subject of the litigation.
Material Changes and Legal Proceedings
The primary material event is the United States government's election on October 17, 2011, to decline intervention in a qui tam claim filed by Richard J. Klein, Omeros' former Chief Financial Officer. Key details include:
- Allegations: Mr. Klein alleged violations of the Federal False Claims Act regarding NIH grants and wrongful discharge in violation of public policy.
- Government Action: The U.S. declined to take over the action, though Mr. Klein may continue the qui tam suit independently.
- Company Response: Omeros denies the allegations and asserts substantial defenses. The company has filed counterclaims against Mr. Klein for breach of contract, misappropriation of trade secrets, and breach of fiduciary duty.
- Procedural Status: The complaint and declination notice were unsealed on October 21, 2011. Non-executive directors were previously dismissed from the case with prejudice in 2010.
Outlook, Risks, and Management Commentary
Management states that neither the outcome of the litigation nor the potential range of damages can be assessed with certainty. The filing directs investors to the Form 10-Q filed on August 9, 2011, for additional details on legal proceedings. The government's declination does not impact Omeros' counterclaims or Mr. Klein's other claims.
Investor Verification Checklist
- Review the Form 10-Q filed on August 9, 2011, for comprehensive details on the legal proceedings.
- Monitor the status of the unsealed qui tam complaint in the U.S. District Court for the Western District of Washington.
- Assess the potential financial exposure of the $1.3 million NIH grant dispute and associated legal costs.
- Track the progress of Omeros' counterclaims against the former CFO.